Oragenics : Statement of Changes in Beneficial Ownership (Form 4)
May 26, 2022 at 12:18 am EDT
Share
Ownership Submission
FORM 4
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**)
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging between $0.2800 and $0.3000 on May 24, 2022. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Oragenics Inc. published this content on 25 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2022 04:15:20 UTC.
Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product NT-CoV2-1 is an intranasal vaccine candidate to prevent coronavirus disease (COVID-19) from the SARS-CoV-2 virus and variants thereof. Its lantibiotics program features a novel class of antibiotics against bacteria its research has shown may be applicable to multiple antibiotic-resistant organisms. Its Antibiotics product is a semi-synthetic analog of MU1140, which is a member of lantibiotic class of antibiotics. Its product pipeline also includes ONP-002, which is a fully synthetic neurosteroid being developed to treat mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC). Through its wholly owned subsidiary, Noachis Terra, is engaged in the research and development stage for its new Terra CoV-2 and NT-CoV2-1 vaccine product candidates.